A new trading day began on Friday, with Zevra Therapeutics Inc (NASDAQ: ZVRA) stock price down -3.02% from the previous day of trading, before settling in for the closing price of $9.28. ZVRA’s price has ranged from $4.20 to $9.76 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 29.64%. Meanwhile, its annual earnings per share averaged 88.30%. With a float of $54.01 million, this company’s outstanding shares have now reached $54.68 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is 78.84%, operating margin of -177.09%, and the pretax margin is -185.68%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zevra Therapeutics Inc is 1.10%, while institutional ownership is 65.35%. The most recent insider transaction that took place on Jun 26 ’25, was worth 223,920. Before that another transaction happened on Mar 28 ’25, when Company’s Director bought 300 for $7.84, making the entire transaction worth $2,352. This insider now owns 1,800 shares in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 88.30% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Here are Zevra Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach 0.64 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Looking closely at Zevra Therapeutics Inc (NASDAQ: ZVRA), its last 5-days average volume was 0.58 million, which is a jump from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 65.98%.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 81.92%, which indicates a significant increase from 31.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.79% in the past 14 days, which was lower than the 46.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.34, while its 200-day Moving Average is $8.16. However, in the short run, Zevra Therapeutics Inc’s stock first resistance to watch stands at $9.20. Second resistance stands at $9.41. The third major resistance level sits at $9.56. If the price goes on to break the first support level at $8.84, it is likely to go to the next support level at $8.69. Should the price break the second support level, the third support level stands at $8.48.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
With a market capitalization of 492.12 million, the company has a total of 54,680K Shares Outstanding. Currently, annual sales are 23,610 K while annual income is -105,510 K. The company’s previous quarter sales were 20,400 K while its latest quarter income was -3,100 K.
